Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (31-40 of 288) with videos related to

Pageof 29
Sort By:
Cancer Cell|December 16, 2010
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record timeDavid E Gerber, John D Minna
JCO Oncology Practice|January 6, 2022
Reply to A. Grand et alErin F Williams, David E Gerber
JAMA Oncology|June 1, 2023
Approaches to Continuing COVID-19-Related Clinical Research Practices After the Pandemic-Must Cinderella Leave the Ball?David E Gerber, Elizabeth K S Barksdale
Clinical Chemistry|January 4, 2024
Emerging Strategies in Lung Cancer Screening: Blood and BeyondSheena Bhalla, Sofia Yi, David E Gerber
Clinical Chemistry|February 28, 2024
Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important EntityMitchell S von Itzstein, David E Gerber
Translational Lung Cancer Research|March 11, 2026
A new therapeutic approach to <i>KRAS</i> mutant non-small cell lung cancer: the emerging role of exportin 1 inhibitionMitchell S von Itzstein, David E Gerber
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 21, 2019
Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?Tri Le, John D Minna, David E Gerber
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Management and future directions in non-small cell lung cancer with known activating mutationsDavid E Gerber, Leena Gandhi, Daniel B Costa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2022
Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?Sherry Fu, David E Gerber, Muhammad Shaalan Beg
The Lancet. Respiratory Medicine|June 2, 2018
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapySawsan Rashdan, John D Minna, David E Gerber
Pageof 29

Showing results (31-40 of 288) with videos related to

Sort By:
Pageof 29
Cancer Cell|December 16, 2010
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record timeDavid E Gerber, John D Minna
JCO Oncology Practice|January 6, 2022
Reply to A. Grand et alErin F Williams, David E Gerber
JAMA Oncology|June 1, 2023
Approaches to Continuing COVID-19-Related Clinical Research Practices After the Pandemic-Must Cinderella Leave the Ball?David E Gerber, Elizabeth K S Barksdale
Clinical Chemistry|January 4, 2024
Emerging Strategies in Lung Cancer Screening: Blood and BeyondSheena Bhalla, Sofia Yi, David E Gerber
Clinical Chemistry|February 28, 2024
Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important EntityMitchell S von Itzstein, David E Gerber
Translational Lung Cancer Research|March 11, 2026
A new therapeutic approach to <i>KRAS</i> mutant non-small cell lung cancer: the emerging role of exportin 1 inhibitionMitchell S von Itzstein, David E Gerber
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 21, 2019
Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?Tri Le, John D Minna, David E Gerber
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Management and future directions in non-small cell lung cancer with known activating mutationsDavid E Gerber, Leena Gandhi, Daniel B Costa
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2022
Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?Sherry Fu, David E Gerber, Muhammad Shaalan Beg
The Lancet. Respiratory Medicine|June 2, 2018
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapySawsan Rashdan, John D Minna, David E Gerber
Pageof 29